<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37159497</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Advantages of routine next-generation sequencing over standard genetic testing in the amyotrophic lateral sclerosis clinic.</ArticleTitle><Pagination><StartPage>2240</StartPage><EndPage>2249</EndPage><MedlinePgn>2240-2249</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15855</ELocationID><Abstract><AbstractText Label="BACKGROUND">Next-generation sequencing has enhanced our understanding of amyotrophic lateral sclerosis (ALS) and its genetic epidemiology. Outside the research setting, testing is often restricted to those who report a family history. The aim of this study was to explore the added benefit of offering routine genetic testing to all patients in a regional ALS centre.</AbstractText><AbstractText Label="METHODS">C9ORF72 expansion testing and exome sequencing was offered to consecutive patients (150 with ALS and 12 with primary lateral sclerosis [PLS]) attending the Oxford Motor Neuron Disease Clinic within a defined time period.</AbstractText><AbstractText Label="RESULTS">A total of 17 (11.3%) highly penetrant pathogenic variants in C9ORF72, SOD1, TARDBP, FUS and TBK1 were detected, of which 10 were also found through standard clinical genetic testing pathways. The systematic approach resulted in five additional diagnoses of a C9ORF72 expansion (number needed to test [NNT]&#x2009;=&#x2009;28), and two further missense variants in TARDBP and SOD1 (NNT&#x2009;=&#x2009;69). Additionally, 3 patients were found to carry pathogenic risk variants in NEK1, and 13 patients harboured common missense variants in CFAP410 and KIF5A, also associated with an increased risk of ALS. We report two novel non-coding loss-of-function splice variants in TBK1 and OPTN. No relevant variants were found in the PLS patients. Patients were offered double-blinded participation, but &gt;80% requested disclosure of the results.</AbstractText><AbstractText Label="CONCLUSIONS">This study provides evidence that expanding genetic testing to all patients with a clinical diagnosis of ALS enhances the potential for recruitment to clinical trials, but will have direct resource implications for genetic counselling.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scaber</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0146-1821</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrimond</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5905-3826</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proudfoot</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossher</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BRC127/NS/NW/5992</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500506">KIF5A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">whole exome sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37159497</ArticleId><ArticleId IdType="doi">10.1111/ene.15855</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Talbot K, Feneberg E, Scaber J, Thompson AG, Turner MR. Amyotrophic lateral sclerosis: the complex path to precision medicine. J Neurol. 2018;265(10):2454-2462. doi:10.1007/s00415-018-8983-8</Citation></Reference><Reference><Citation>Osler W. On heredity in progressive muscular atrophy as illustated in the Farr family of Vermont. Arch Med. 1880;4(3):316-320.</Citation></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623-627. doi:10.1136/jnnp.2010.224501</Citation></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Hardiman O. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Amp Psychiatry. 2012;83(4):365-367. doi:10.1136/jnnp-2011-301530</Citation></Reference><Reference><Citation>Zou Z-Y, Zhou Z-R, Che C-H, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540-549. doi:10.1136/jnnp-2016-315018</Citation></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324-3246. doi:10.1136/jnnp.2010.207464</Citation></Reference><Reference><Citation>Trabjerg BB, Garton FC, Van Rheenen W, et al. ALS in Danish registries. Neurol Genetics. 2020;6(2):e398. doi:10.1212/nxg.0000000000000398</Citation></Reference><Reference><Citation>Brenner D, Weishaupt JH. Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol. 2019;32(5):735-739. doi:10.1097/wco.0000000000000737</Citation></Reference><Reference><Citation>Kenna KP, Van Doormaal PTC, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1037-1042. doi:10.1038/ng.3626</Citation></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124-130. doi:10.1038/s41586-022-04424-7</Citation></Reference><Reference><Citation>Coutelier M, Hammer MB, Stevanin G, et al. Efficacy of exome-targeted capture sequencing to detect mutations in known cerebellar ataxia genes. JAMA Neurol. 2018;75(5):591-599. doi:10.1001/jamaneurol.2017.5121</Citation></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:178.e11-178.e20. doi:10.1016/j.neurobiolaging.2016.12.013</Citation></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510-518. doi:10.1136/jnnp-2020-325014</Citation></Reference><Reference><Citation>Grassano M, Calvo A, Moglia C, et al. Mutational analysis of known ALS genes in an Italian population-based cohort. Neurology. 2021;96(4):e600-e609. doi:10.1212/WNL.0000000000011209</Citation></Reference><Reference><Citation>Lattante S, Marangi G, Doronzio PN, et al. High-throughput genetic testing in ALS: the challenging path of variant classification considering the ACMG guidelines. Genes. 2020;11(10):1123. doi:10.3390/genes11101123</Citation></Reference><Reference><Citation>Bartoletti-Stella A, Vacchiano V, De Pasqua S, et al. Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. J Neurol. 2021;268:3766-3776. doi:10.1007/s00415-021-10521-w</Citation></Reference><Reference><Citation>Morgan S, Shatunov A, Sproviero W, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140(6):1611-1618. doi:10.1093/brain/awx082</Citation></Reference><Reference><Citation>Efficient Architecture-Aware Acceleration of BWA-MEM for Multicore Systems. IEEE; 2019.</Citation></Reference><Reference><Citation>Van de Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high-confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(1110):11.10.1-11.10.33. doi:10.1002/0471250953.bi1110s43</Citation></Reference><Reference><Citation>McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:10.1186/s13059-016-0974-4</Citation></Reference><Reference><Citation>Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176(3):535-48.e24. doi:10.1016/j.cell.2018.12.015</Citation></Reference><Reference><Citation>Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12(1):103. doi:10.1186/s13073-020-00803-9</Citation></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33(9):1345-1351. doi:10.1002/humu.22157</Citation></Reference><Reference><Citation>McCann EP, Henden L, Fifita JA, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet. 2021;58(2):87-95. doi:10.1136/jmedgenet-2020-106866</Citation></Reference><Reference><Citation>Schwarz JM, R&#xf6;delsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575-576. doi:10.1038/nmeth0810-575</Citation></Reference><Reference><Citation>Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics. 2010;26(7):873-881. doi:10.1093/bioinformatics/btq057</Citation></Reference><Reference><Citation>Ng PC. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-3814. doi:10.1093/nar/gkg509</Citation></Reference><Reference><Citation>Rogers MF, Shihab HA, Mort M, Cooper DN, Gaunt TR, Campbell C. FATHMM-XF: accurate prediction of pathogenic point mutations via extended features. Bioinformatics. 2018;34(3):511-513. doi:10.1093/bioinformatics/btx536</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-423. doi:10.1038/gim.2015.30</Citation></Reference><Reference><Citation>Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. Genome Med. 2020;12(1):62. doi:10.1186/s13073-020-00761-2</Citation></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631-636. doi:10.1038/nn.4000</Citation></Reference><Reference><Citation>Belzil VV, Daoud H, Desjarlais A, et al. Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiol Aging. 2011;32(3):555.e13-555.e14. doi:10.1016/j.neurobiolaging.2010.10.001</Citation></Reference><Reference><Citation>Brenner D, M&#xfc;ller K, Wieland T, et al. NEK1mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139(5):e28. doi:10.1093/brain/aww033</Citation></Reference><Reference><Citation>Teyssou E, Muratet F, Amador M-D-M, et al. Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiol Aging. 2021;99:102.e11-102.e20. doi:10.1016/j.neurobiolaging.2020.10.015</Citation></Reference><Reference><Citation>Smith BN, Topp SD, Fallini C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(388):eaad9157. doi:10.1126/scitranslmed.aad9157</Citation></Reference><Reference><Citation>Nahm M, Lim SM, Kim Y-E, et al. ANXA11mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics. Sci Transl Med. 2020;12(566):eaax3993. doi:10.1126/scitranslmed.aax3993</Citation></Reference><Reference><Citation>Feneberg E, Turner MR, Ansorge O, Talbot K. Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology. 2020;95(13):595-596. doi:10.1212/wnl.0000000000010587</Citation></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91(4):373-377. doi:10.1136/jnnp-2019-322541</Citation></Reference><Reference><Citation>Van Rheenen W, Van Der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636-1648. doi:10.1038/s41588-021-00973-1</Citation></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069-1075. doi:10.1038/nature09320</Citation></Reference><Reference><Citation>Burke W, Parens E, Chung WK, Berger SM, Appelbaum PS. The challenge of genetic variants of uncertain clinical significance: a narrative review. Ann Intern Med. 2022;175(7):994-1000. doi:10.7326/M21-4109</Citation></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry. 2017;88(12):1042-1044. doi:10.1136/jnnp-2017-315995</Citation></Reference><Reference><Citation>Dharmadasa T, Scaber J, Edmond E, et al. Genetic testing in motor neurone disease. Pract Neurol. 2022;22(2):107-116. doi:10.1136/practneurol-2021-002989</Citation></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al. Genetic testing in ALS. Neurology. 2017;88(10):991-999. doi:10.1212/wnl.0000000000003686</Citation></Reference><Reference><Citation>Henden L, Twine NA, Szul P, et al. Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. NPJ Genomic Med. 2020;5(32). doi:10.1038/s41525-020-00139-8</Citation></Reference><Reference><Citation>Nakamura S, Wate R, Kaneko S, et al. An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T&#x2009;SOD1mutation. Neuropathology. 2014;34(1):58-63. doi:10.1111/neup.12049</Citation></Reference><Reference><Citation>Orrell RW, King AW, Hilton DA, Campbell MJ, Lane RJ, de Belleroche JS. Familial amyotrophic lateral sclerosis with a point mutation of SOD-1: intrafamilial heterogeneity of disease duration associated with neurofibrillary tangles. J Neurol Neurosurg Psychiatry. 1995;59(3):266-270. doi:10.1136/jnnp.59.3.266</Citation></Reference><Reference><Citation>Aoki M, Ogasawara M, Matsubara Y, et al. Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in CuZn superoxide dismutase gene: a possible new subtype of familial ALS. J Neurol Sci. 1994;126(1):77-83. doi:10.1016/0022-510X(94)90097-3</Citation></Reference><Reference><Citation>&#xd8;stern R, Fagerheim T, &#xd8;rstavik K, et al. Hereditary motor neuron disease in a large Norwegian family with a &#x201c;H46R&#x201d; substitution in the superoxide dismutase 1 gene. Neuromuscul Disord. 2012;22(6):511-521. doi:10.1016/j.nmd.2012.01.011</Citation></Reference><Reference><Citation>Gitcho MA, Baloh RH, Chakraverty S, et al. TDP-43A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63(4):535-538. doi:10.1002/ana.21344</Citation></Reference><Reference><Citation>Chi&#xf2; A, Restagno G, Brunetti M, et al. Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. Neurobiol Aging. 2009;30(8):1272-1275. doi:10.1016/j.neurobiolaging.2009.05.001</Citation></Reference><Reference><Citation>Yamashita S, Mori A, Sakaguchi H, et al. Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J Neurol. 2012;259(6):1039-1044. doi:10.1007/s00415-011-6292-6</Citation></Reference><Reference><Citation>Luisa Conforti F, Sprovieri T, Mazzei R, et al. Further evidence that D90A-SOD1 mutation is recessively inherited in ALS patients in Italy. Amyotroph Lateral Scler. 2009;10(1):58-60. doi:10.1080/17482960802163853</Citation></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89(8):817-827. doi:10.1136/jnnp-2017-317611</Citation></Reference><Reference><Citation>Fingert JH, Robin AL, Stone JL, et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. Hum Mol Genet. 2011;20(12):2482-2494. doi:10.1093/hmg/ddr123</Citation></Reference><Reference><Citation>Wu C-H, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488(7412):499-503. doi:10.1038/nature11280</Citation></Reference><Reference><Citation>Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562-578. doi:10.1038/nprot.2012.016</Citation></Reference><Reference><Citation>Van Der Zee J, Gijselinck I, Van Mossevelde S, et al. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum Mutat. 2017;38(3):297-309. doi:10.1002/humu.23161</Citation></Reference><Reference><Citation>Williams KL, Topp S, Yang S, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016;7(1):11253. doi:10.1038/ncomms11253</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>